Article
TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion.
Cancer gene therapy - 1 Jul 2026
Sarkar Debina, Gyanwali Gaurav C, Patel Jaishree, Shevchuk Polina, Jeffs Aaron, Woolley Adele G, Wang Selena, Sardari Maryam, Bhandarkar Apeksha, Siddiqui Halima, Ratajska Magdalena, Sarwar Makhdoom, Kannan Srinivasaraghavan, Verma Chandra S, Drummond Catherine J, McKinney Cushla, Antony Jisha, McCormick Sally P, Braithwaite Antony, Mehta Sunali
Abstract excerpt
Mutations in the tumour suppressor, TP53, are prevalent in human cancers yet their functional implications remain unclear. Through comprehensive pan-cancer database analysis, we identified H179 mutations in TP53 as significantly associated with poor disease-free survival across multiple cancer types. Functional studies in lung, ovarian, and prostate cancer cells over-expressing the p53H179R/Y mutants revealed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.